SAN DIEGO - ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a commercial-stage biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, announced that the National Medical Products Administration (NMPA) in China has granted approval for neffy 2 mg (epinephrine nasal spray) for the emergency treatment of Type 1 allergic reactions (anaphylaxis) in adults and children who weigh 30 kg or more.
In China, the trade name is ??? meaning 'Excellent Allergy (treatment) Fast'e>30 December 2025/
(C) 2025 Electronic News Publishing, source ENP Newswire